Correction: LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/ miR-324-3p-SIRT5 axis in lung adenocarcinoma.

Wu, Jie; Zheng, Chunlei; Wang, Yizhe; Yang, Zichang; Li, Ce; Fang, Wanxia; Jin, Yue; Hou, Kezuo; Cheng, Yang; Qi, Jianfei; Qu, Xiujuan; Liu, Yunpeng; Che, Xiaofang; Hu, Xuejun

Wu, Jie; Zheng, Chunlei; Wang, Yizhe; Yang, Zichang; Li, Ce; Fang, Wanxia; Jin, Yue; Hou, Kezuo; Cheng, Yang; Qi, Jianfei; Qu, Xiujuan; Liu, Yunpeng; Che, Xiaofang; Hu, Xuejun.

Afiliación

Wu J; Department of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, No.155 Nanjing North Street, Heping District, Shenyang, 110001, Liaoning, China.
Zheng C; Department of Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, 121000, Liaoning, China.
Wang Y; Department of Medical Oncology, The First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
Yang Z; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
Li C; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, Liaoning, China.
Fang W; Department of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, No.155 Nanjing North Street, Heping District, Shenyang, 110001, Liaoning, China.
Jin Y; Department of Medical Oncology, The First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
Hou K; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
Cheng Y; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, Liaoning, China.
Qi J; Department of Medical Oncology, The First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
Qu X; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
Liu Y; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, Liaoning, China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
Hu X; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.

Biomark Res ; 11(1): 51, 2023 May 12.

Article en En | MEDLINE | ID: mdl-37173742

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomark Res Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google